CATEGORY: Featured Tuesday, January 9, 2018 5:13 pm EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends to offer shares of its common stock in a public offering. H.C. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-01-09 01:24:442018-02-23 01:25:04AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock
Seven patients with serious, life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01, with six patients, 86%, achieving treatment success Treatment was well tolerated in all patients, with over 500 doses administered intravenously or by inhalation AmpliPhi expects to continue its expanded access clinical strategy in 2018, review data with the FDA […]
21 Dec 2017 San Mateo, CA – December 20, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today highlighted milestones achieved in advance of 2018. “As we conclude December and the calendar year, we are accelerating realization of our vision of stronger partnerships between patients and physicians, facilitated by […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2017-12-21 01:17:032019-02-13 12:36:25Adherium Highlights Milestones Achieved in Advance of 2018
Under single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018 Company expects to continue its expanded access clinical strategy in 2018, review data with FDA in mid-2018 and initiate Phase 2 or […]
Posted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2017-12-01 01:06:572019-02-13 12:36:45China Medical System Holdings Limited invests £3.0 million in Destiny Pharma
Avita Announces Office Transitions in Australia and the UK Decision Optimizes Access to Strategic Markets to Support Long-Term Growth Strategy Valencia, CA, USA, Perth, Australia and London, United Kingdom, 29 November 2017 — Avita Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a platform technology creating opportunities in burn and wound care, and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2017-11-29 00:16:022019-02-13 12:37:01AVITA Announces Office Transitions in Australia and the UK
Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2017-11-14 00:09:572019-02-13 12:37:08AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights
Avita Medical announces Rights Issue raises $12.4 million Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Non-Renounceable Rights Issue. The Board of Avita Medical Limited is pleased […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2017-11-07 00:05:202019-02-13 12:37:24Avita Medical – Rights Issue Raises $12.4 Million
London, UK and Melbourne, Australia, 30 October 2017 – Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers), has announced the expansion of its team with the addition of three new directors with broad sector and geographic experience – Dr Michael Perry as a Director, Dennis Purcell as a Director and Senior Expert Advisor, and […]
Valencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY), – link here a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-09-21 10:00:402018-01-05 13:09:43Avita Medical and BARDA Execute a US$24.3m Contract Option
AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock
/in Armata Pharmaceuticals, Portfolio CompaniesCATEGORY: Featured Tuesday, January 9, 2018 5:13 pm EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends to offer shares of its common stock in a public offering. H.C. […]
AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
/in Armata PharmaceuticalsSeven patients with serious, life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01, with six patients, 86%, achieving treatment success Treatment was well tolerated in all patients, with over 500 doses administered intravenously or by inhalation AmpliPhi expects to continue its expanded access clinical strategy in 2018, review data with the FDA […]
Adherium Highlights Milestones Achieved in Advance of 2018
/in Adherium21 Dec 2017 San Mateo, CA – December 20, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today highlighted milestones achieved in advance of 2018. “As we conclude December and the calendar year, we are accelerating realization of our vision of stronger partnerships between patients and physicians, facilitated by […]
AmpliPhi Biosciences Provides Corporate and Strategic Update
/in Armata PharmaceuticalsUnder single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018 Company expects to continue its expanded access clinical strategy in 2018, review data with FDA in mid-2018 and initiate Phase 2 or […]
China Medical System Holdings Limited invests £3.0 million in Destiny Pharma
/in Destiny PharmaPosted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]
AVITA Announces Office Transitions in Australia and the UK
/in Avita MedicalAvita Announces Office Transitions in Australia and the UK Decision Optimizes Access to Strategic Markets to Support Long-Term Growth Strategy Valencia, CA, USA, Perth, Australia and London, United Kingdom, 29 November 2017 — Avita Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a platform technology creating opportunities in burn and wound care, and […]
AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights
/in Armata PharmaceuticalsSix patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]
Avita Medical – Rights Issue Raises $12.4 Million
/in Avita MedicalAvita Medical announces Rights Issue raises $12.4 million Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Non-Renounceable Rights Issue. The Board of Avita Medical Limited is pleased […]
BioScience Managers Expands Team, Adding Significant New International Expertise
/in BioSciences ManagersLondon, UK and Melbourne, Australia, 30 October 2017 – Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers), has announced the expansion of its team with the addition of three new directors with broad sector and geographic experience – Dr Michael Perry as a Director, Dennis Purcell as a Director and Senior Expert Advisor, and […]
Avita Medical and BARDA Execute a US$24.3m Contract Option
/in Avita Medical, Portfolio CompaniesValencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY), – link here a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes […]